Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Controlled and matched powder Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Lu AG22515 in Healthy Adults

NCT05136053
View directory record Official record
Conditions
Healthy Participants
Interventions
Lu AG22515, Placebo, Immune System Activator
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
19 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users

NCT01596673
View directory record Official record
Conditions
Drug Abuse
Interventions
45-mg hydrocodone bitartrate extended-release tablet (crushed or intact), Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 1, 2026, 10:02 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01090310
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 1, 2026, 10:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints

NCT06946017
View directory record Official record
Conditions
Digestive Health, Quality of Life
Interventions
Fermented dairy protein with prebiotic fiber supplement, Control placebo
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 50 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 1, 2026, 10:02 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Mosliciguat in PH-ILD

NCT06635850
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions
Mosliciguat, Dry Powder Inhaler, Placebo
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

NCT05147805
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Early Phase 1 Interventional

Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome

NCT05377112
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
SYNB8802v1, Placebo
Drug · Other
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Phase 2 Interventional

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

NCT01349868
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®), Placebo MDI
Drug · Other
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Clearwater, Florida • Tampa, Florida • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Oct 1, 2026, 10:02 PM EDT
Terminated Phase 2 Interventional Results available

Vitamin D and n-3 Polyunsaturated Fatty Acids (PUFAs) to Prevent Chronic Pain Following Major Thermal Burn Injury

NCT03313076
View directory record Official record
Conditions
Chronic Pain Following Thermal Burn Injury
Interventions
Omega-3 fatty acids (fish oil), Vitamin D3 (cholecalciferol), Vitamin D3 (cholecalciferol) placebo, Omega-3 fatty acid placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Phase 1 Interventional

Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study

NCT01956305
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DS-7309, placebo, Metformin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Phase 2 Interventional

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

NCT04530123
View directory record Official record
Conditions
Celiac Disease
Interventions
Placebo, TAK-101, Gluten
Drug · Dietary Supplement
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Escondido, California • Poway, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

NCT07344558
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
MNKD-201(Nintedanib DPI), Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
40 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Fresno, California • Palm Springs, California • Doral, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

NCT05934526
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, Seralutinib, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sex-Divergent Effects of Magnesium L-Threonate Supplementation on Sleep Quality, Cognitive Performance, and Neuromuscular Function in Healthy Adults

NCT07706283
View directory record Official record
Conditions
Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular Function
Interventions
Magnesium L-threonate, Placebo
Dietary Supplement
Lead sponsor
Barry University
Other
Eligibility
18 Years to 45 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami Shores, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 1, 2026, 10:02 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289482
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Not applicable Interventional

The Health Effects of Blueberry Anthocyanins in Metabolic Syndrome (the CIRCLES-study)

NCT02035592
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome X
Interventions
Full dose blueberry, Half dose blueberry, Control
Other
Lead sponsor
University of East Anglia
Other
Eligibility
50 Years to 74 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 1, 2026, 10:02 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

SOAR-2: Intervening in Obesity Through Reduction of Dietary Branched Chain Amino Acids

NCT04424537
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
Control diet, Low branched-chain amino acids(BCAA) diet, Low protein diet
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
30 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

Inositol in Trichotillomania

NCT01875445
View directory record Official record
Conditions
Trichotillomania, Hair Pulling
Interventions
Inositol, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Phase 3 Interventional Results available

NVA237 BID Versus Placebo Twelve-week Efficacy Study

NCT01715298
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
59
States / cities
*See Various Dept.'s*, Arizona • Chandler, Arizona • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia

NCT04158687
View directory record Official record
Conditions
Schizophrenia
Interventions
CTP-692, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
26
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB

NCT03017170
View directory record Official record
Conditions
Overactive Bladder
Interventions
Dried Cranberry, Placebo Oral Capsule
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 1, 2026, 10:02 PM EDT
Recruiting Not applicable Interventional

Effects of Ketone Ester Consumption on Exercise Tolerance and Cardiac Function

NCT06078683
View directory record Official record
Conditions
Type 2 Diabetes, Ketone Body Metabolism, Ketones, Metabolism
Interventions
Ketone Ester Acute, Placebo Acute
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 1, 2026, 10:02 PM EDT
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

NCT04456673
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
92
States / cities
Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 1, 2026, 10:02 PM EDT
Terminated Phase 3 Interventional Results available

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

NCT00886769
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 1, 2026, 10:02 PM EDT